Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiangiogenic therapy in the management of breast cancer.
Wu Y, Sun WL, Feng JF. Wu Y, et al. Among authors: feng jf. Asia Pac J Clin Oncol. 2013 Jun;9(2):110-6. doi: 10.1111/j.1743-7563.2012.01569.x. Epub 2012 Jul 9. Asia Pac J Clin Oncol. 2013. PMID: 22898270 Review.
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Hu XC, et al. Among authors: feng jf. Lancet Oncol. 2015 Apr;16(4):436-46. doi: 10.1016/S1470-2045(15)70064-1. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795409 Clinical Trial.
Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH, Wang DD, Yan DL, Hu Y, Yang SJ, Liu SW, Feng JF. Sha HH, et al. Among authors: feng jf. Biosci Rep. 2017 Jan 27;37(1):BSR20160332. doi: 10.1042/BSR20160332. Print 2017 Feb 28. Biosci Rep. 2017. PMID: 28053197 Free PMC article. Review.
China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version).
Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, Wang D, Wang C, Wang Z, Wang M, Zhi X, Lu Y, Feng J, Liu Y, Liu X, Liu W, Wu G, Li X, Li K, Li E, Li W, Chen G, Chen Z, Yu P, Wu N, Wu M, Xiao W, Zhang L, Zhang Y, Zhang S, Yang S, Song X, Lin D, Luo R, Shan L, Zhou C, Zhou Z, Zhao Q, Hu C, Hu Y, Guo Q, Chang J, Huang C, Zeng X, Han B, Han X, Jia B, Han Y, Huang Y. Shi Y, et al. Asia Pac J Clin Oncol. 2017 Feb;13(1):87-103. doi: 10.1111/ajco.12608. Epub 2016 Nov 7. Asia Pac J Clin Oncol. 2017. PMID: 28134505 No abstract available.
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X. Jiang Z, et al. Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27. Lancet Oncol. 2019. PMID: 31036468 Clinical Trial.
522 results